# EDGAR Filing Document

**Accession Number:** 0001512762
**File Stem:** 0001104659-26-003117
**Filing Date:** 2026-1
**Character Count:** 10371
**Document Hash:** 525e096536a52f8030982dac3ca4bb5f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-003117.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001104659-26-003117

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20260113

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coherus Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001512762
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273615821
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36721
- **FILM NUMBER:** 26528557

**BUSINESS ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** (650) 649-3530

**MAIL ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Coherus BioSciences, Inc.
- **DATE OF NAME CHANGE:** 20130114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioGenerics, Inc.
- **DATE OF NAME CHANGE:** 20110210

?xml version='1.0' encoding='ASCII'? COHERUS ONCOLOGY, INC._January 13, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 13, 2026**

## COHERUS ONCOLOGY, INC.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36721** | **27-3615821** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification Number)** |

---

**333 Twin Dolphin Drive, Suite 600**

**Redwood City, CA 94065**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (650) 649-3530**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, $0.0001 par value per share** | **CHRS** | **The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition**

Coherus Oncology, Inc. (the "Company") will include its preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, and cash, cash equivalents and investments as of December 31, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in this presentation is furnished as Exhibit 99.1 to this report.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Cautionary Note Regarding Preliminary Unaudited Financial Results**

The Company is providing the preliminary financial information for the quarter and fiscal year ended December 31, 2025 and as of December 31, 2025 based on currently available information. The Company's financial closing procedures for the quarter and fiscal year ended December 31, 2025 are not yet complete. These procedures may result in changes that could significantly affect such preliminary unaudited results. As a result, the Company's final results for the quarter and fiscal year ended December 31, 2025 and as of December 31, 2025 may vary materially from the preliminary unaudited results furnished in Exhibit 99.1. The Company's independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement.

**Forward-Looking Statements**

Certain information included in the slide attached as Exhibit 99.1 to this Current Report constitutes forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including projected revenue growth of LOQTORZI. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the Company's ability to raise funds, which may not be available on acceptable terms or at all; the risks and uncertainties of the degree of market acceptance for the Company's product by physicians, healthcare providers and patients; and the risks and uncertainties of litigation. All such forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, see the filings the Company makes with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports on Form 10-Q and the sections therein entitled "Risk Factors".

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](chrs-20260113xex99d1.htm) | [Slide from Company presentation.](chrs-20260113xex99d1.htm) |
| 104 | Cover page Interactive Data file (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 13, 2026 | COHERUS ONCOLOGY, INC. | COHERUS ONCOLOGY, INC. |
|  | By: | /s/ Dennis M. Lanfear |
|  | Name: | Dennis M. Lanfear |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

#### Exhibit 99.1

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](chrs-20260113xex99d1g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;©2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Commercial Stage Clinical Stage Tagmokitug • HNSCC – Mid 2026 • GC, GEJ, EAC – Mid 2026 • CRC – H2 2026 • ESCC – H2 2026 • Additional indications starting in 2026 Casdozokitug • HCC – Mid 2026 Tagmokitug novel combinations Ex-US licensing LOQTORZI® US supply agreements NPC = Nasopharyngeal Carcinoma; HNSCC = Head and Neck Squamous Cell Carcinoma; GC = Gastric Cancer; GEJ = Gastro-esophageal-junction; EAC = Esophageal Adenocarcinoma; ESCC = Esophageal Squamous Cell Carcinoma; HCC = Hepatocellular Carcinoma; sqNSCLC = squamous Non-Small Cell Lung Cancer $172.1M\* in cash, cash equivalents and investments at the end of Q4 2025, expected to support operations through end of 2026 \* Cash, cash equivalents and investments as of December 31, 2025, inclusive of Transition Service Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities. The preliminary fourth quarter and full year 2025 financial information presented herein has not been audited and is subject to change |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](chrs-20260113xex99d1g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;©2025 Coherus©2026 Coherus Oncology, Inc. 2 LOQTORZI® Delivering Steady Demand and Revenue Growth Projected to Reach $150-200M in Revenues by 2028 in $250M Market 2024 2025\* 2028 19.1 ~40.8 150-200 0 50 100 150 Strong demand growth for LOQTORZI supported by data strength and commercial efforts Resulting in steady revenue growth, projected to ~$150-200 million by 2028 Q1 Q2 Q3 Q4\* 7.3 10.0 11.2 ~12.3 LOQTORZI Annual Revenues (US$ M) 2025 Quarterly LOQTORZI Revenues (US$ M) Projected 10-15% QoQ growth LOQTORZI Demand Trend +16% +19% +12% +15% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 \* Q4 and full year 2025 financial information presented herein is preliminary and has not been audited and is subject to change |

---